ClinicalTrials.gg
Active, not recruitingNCT02102113Updated Nov 12, 2026

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

An Early Phase 1 interventional study of Placebo and Very Low Dose THC in Psychosis, Cannabis Use and THC, sponsored by Yale University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Yale University · Early Phase 1, Interventional, and Other

How we know

Updated Nov 12, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing dronabinol in Psychotic Disorders — none open to participants now, 2 under way, none of them phase 3. Dronabinol · Psychotic Disorders.

Enrollment
6th of 10
27 · median 33
Started
2014
with 2 others
Phase 1
10 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
8 of 10
Yale University

Among the 10 studies testing dronabinol in Psychotic Disorders, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 1, and was the 7th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

None of the 10 studies testing dronabinol in Psychotic Disorders is open now. The open studies under Psychotic Disorders, anywhere →

Where they have run

About dronabinol

Dronabinol: first FDA approval 1985 (MARINOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing dronabinol in Psychotic Disorders as a file.
02

Study summary

The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.

03

Conditions studied

  • Psychosis
  • Cannabis Use
  • THC
  • Marijuana
  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria FHP:

  • Exposure to cannabis at least once in their lifetime
  • Medically and psychiatrically healthy based on screening
  • Having one relative with a confirmed psychotic disorder

Exclusion Criteria FHP:

  • Current or lifetime major Axis I disorder
  • Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
  • Major or unstable medical illness that might impact safety of the subject in the study
  • Cannabis naive
  • IQ less than 85
  • Less than a high school diploma or its educational equivalent
  • Pregnancy or lactation
  • Major current or recent (\<6 weeks) psychosocial stressors.

Inclusion Criteria FHN :

  • Exposure to cannabis at least once in their lifetime
  • Medically and psychiatrically healthy based on screening

Exclusion Criteria FHN:

  • Having a family member with psychosis
  • Current or lifetime major DSM-IV Axis I disorder
  • Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
  • Major or unstable medical illness that might impact safety of the subject in the study
  • Cannabis naive
  • IQ less than 85
  • Less than a high school diploma or its educational equivalent
  • Pregnancy or lactation
  • Major current or recent (\<6 weeks) psychosocial stressors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
27 participants (actual)

Study arms

  • Other
    No Family History of Psychosis (FHN)

    Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.

    Drug: Placebo · Drug: Very Low Dose THC · Drug: Low Dose THC

  • Experimental
    Family History of Psychosis (FHP)

    Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.

    Drug: Placebo · Drug: Very Low Dose THC · Drug: Low Dose THC

Interventions

06

What researchers measure

Primary outcomes

  1. Positive and Negative Symptom Scale for Schizophrenia (PANSS)

    Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.

    Time frame: -30 min from administration of THC

  2. Positive and Negative Symptom Scale for Schizophrenia (PANSS)

    Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.

    Time frame: +80 min from administration of THC

  3. Positive and Negative Symptom Scale for Schizophrenia (PANSS)

    Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.

    Time frame: +150 min of administration of THC

  4. Positive and Negative Symptom Scale for Schizophrenia (PANSS)

    Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS.

    Time frame: +240 min of administration of THC

Secondary outcomes

  1. Clinician Administered Dissociative Symptoms Scale (CADSS)

    Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items (0=not at all, 4=extremely). The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.

    Time frame: -30 min, +15 min, +80 min, +150 min, +240 min

  2. Visual Analog Scale (VAS)

    Feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states ("high", "anxious", "calm and relaxed", and "tired") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11 mm line (0=not at all, 100=extremely). These data will be captured to validate that the experiment is relevant to cannabis effects.

    Time frame: -30 min, +15 min, +80 min, +150 min, +240 min

  3. Hopkins Verbal Learning Test (HVLT)

    The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials, an interference list, and free delayed recall and recognition. A different version of the AVLT will be administered on each test day and counterbalanced across subjects.

    Time frame: +50 min

  4. Psychotomimetic States Inventory (PSI)

    The PSI is a measure of drug induced psychotomimetic states. This self-report scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC.

    Time frame: -30 min, +240 min

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Jan 2014, a primary completion of Jun 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2026 → Jun 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2014
First posted
Apr 2, 2014
Start
Jan 2014
Primary completionEst.
Jun 2028was Jun 2026
CompletionEst.
Dec 2028was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2028
Nov 12, 2026
Study completion
Dec 2026→Dec 2028
Nov 12, 2026
Enrollment
21 (estimated)→27 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jun 2026→Jun 2028
    Study completion Dec 2026→Dec 2028
    Enrollment 21 (estimated)→27 (actual)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02102113
Lead sponsor
Yale University
Collaborators
VA Connecticut Healthcare System
Responsible party
Mohini Ranganathan (Assistant Professor of Psychiatry, Yale University) — Principal investigator
First posted
Apr 2, 2014
Start date
Jan 2014
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Mohini Ranganathan, MD
principal investigator · Yale University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion